Results 191 to 200 of about 17,427,068 (314)

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Communicating With Patients Who Prefer a Language Other than English: A Curriculum on Interpreter Use for Medical Students. [PDF]

MedEdPORTAL
Bravo CG, Ramirez S, Sandgren KE, Conrad AL, Schmitz A.   +4 more
europepmc   +1 more source

Report of the Task Force on Ethical and Religious Directives [PDF]

, 2005
Catholic Medical Association
core   +1 more source

Direct ophthalmoscopy should be taught to undergraduate medical students—No [PDF]

, 2015
Robert Purbrick, Victor Chong
openalex   +1 more source

Medical commitments Medical commitments Medical commitments

Archives of Advances in Biosciences, 2012
openaire   +1 more source

Medical rehabilitation

Journal of Rehabilitation Medicine, 1969
openaire   +3 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Correction: Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. [PDF]

Signal Transduct Target Ther
Yang Y, Wu Y, Zhao J, Zhang T, Fei K, Zhao X, Deng L, Zhang Z, Jiang Y, Wang J, Liu W, Wang X, Wang S, Bao H, Wu X, Zhu M, Ou Q, Tang W, Wang L, Wang Z, Bi N.   +20 more
europepmc   +1 more source

Address of John Paul II to the Participants in the International Congress on Life-Sustaining Treatments and Vegetative State: Scientific Advances and Ethical Dilemmas [PDF]

, 2004
Catholic Medical Association
core   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source